(Q34380709)

1 August 2017

Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial (English)

1 reference

1 August 2017

Anjali Lepcha

1

1 reference

1 August 2017

Sophia Amalanathan

2

1 reference

1 August 2017

Ann Mary Augustine

3

1 reference

1 August 2017

Amit Kumar Tyagi

4

1 reference

1 August 2017

Achamma Balraj

5

1 reference

1 August 2017

29 October 2013

1 reference

1 August 2017

6

1 reference

European Archives of Oto-Rhino-Laryngology

inferred from page(s)

published in

1 reference

1 August 2017

271

1 reference

1 August 2017

11

1 reference

1 August 2017

2931-2936

1 reference

https://scigraph.springernature.com/pub.10.1007/s00405-013-2786-4

1 August 2017

0 references

cites work

The interrelations of migraine, vertigo, and migrainous vertigo.

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Episodic vertigo related to migraine (90 cases): vestibular migraine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Migraine-related vestibulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

21 January 2018

Benign recurrent vertigo

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Familial benign recurrent vertigo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

The International Classification of Headache Disorders, 3rd edition (beta version)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Vestibular migraine: a critical review of treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Comparison of flunarizine and topiramate for the prophylaxis of pediatric migraines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Calcium channel blocker use and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Calcium channel blockers and beta-blockers in relation to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Medical management of migraine-related dizziness and vertigo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Chronic migrainous vertigo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Migraine-associated dizziness: patient characteristics and management options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Management of vestibular migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Objective evaluation of the effect of flunarizine on vestibular neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

The pharmacological treatment of migraine in children and adolescents: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Update on the prophylaxis of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Protection of flunarizine on cerebral mitochondria injury induced by cortical spreading depression under hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00405-013-2786-4

Migraine-associated dizziness

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of migraine with prophylactic drugs

1 reference

12 December 2020

Flunarizine in migraine prophylaxis: predictive factors for a positive response

1 reference

12 December 2020

Neuro-otological findings in patients with migraine- and nonmigraine-related dizziness

1 reference

12 December 2020

Flunarizine in the treatment of vestibular vertigo: experimental and clinical data

1 reference

12 December 2020

Effects of valproate on vestibular symptoms and electronystagmographic findings in migraine patients

1 reference

12 December 2020

1 reference

12 December 2020

The International Classification of Headache Disorders: 2nd edition

1 reference

12 December 2020

Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: A possible locus of action in the prevention of migraine

1 reference

12 December 2020

Familial migraine with vertigo and essential tremor

1 reference

12 December 2020

Vestibular migraine: diagnostic criteria.

1 reference

12 December 2020

How caloric vestibular irritation influences migraine attacks

1 reference

12 December 2020

Flunarizine in migraine prophylaxis: the clinical experience

1 reference

12 December 2020

Vestibular rehabilitation for migraine-associated dizziness

1 reference

12 December 2020

Betahistine in the treatment of vertiginous syndromes: a meta-analysis

1 reference

12 December 2020

A novel CACNA1A mutation results in episodic ataxia with migrainous features without headache

1 reference

12 December 2020

Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine

1 reference

12 December 2020

Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial.

1 reference

12 December 2020

10.1007/S00405-013-2786-4

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference